P2Y2 receptor agonists: A new class of medication targeted at improved mucociliary clearance

Chest

Volumn 121, Issue 5 SUPPL., 2002, Pages 201S-205S

  Kellerman, Donald J ^a  

^a Inspire Pharmaceuticals   (United States)

Author keywords

Chronic bronchitis; COPD; Cystic fibrosis; INS365; Mucociliary clearance; P2Y receptors; Purinergic receptors; Uridine triphosphate

Indexed keywords

PURINE P2Y RECEPTOR; PURINE P2Y RECEPTOR AGONIST; PURINERGIC RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

CHRONIC BRONCHITIS; CONFERENCE PAPER; HUMAN; LUNG CLEARANCE; MEDICAL RESEARCH; MUCOCILIARY CLEARANCE; MUCUS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

EID: 0036260974     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
2. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicenter, double-blind, placebo-controlled trial
3. A controlled trial of ambroxol in chronic bronchitits
4. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
5. Evaluating the efficacy of mucoactive aerosol therapy
6. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction
7. Long-term oral acetylcysteine in chronic bronchitis, a double-blind controlled study
8. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Disease
9. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled release tablets in patients with chronic bronchitis
10. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
11. The National Mucolytic Study: Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis
12. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
13. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: Official statement of the American Thoracic Society
14. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut
15. Purinergic nerves
16. 2 receptor agonists: Structure, activity and therapeutic utility
17. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis
18. Regulation of transepithelial ion transport and extracellular ATP in human normal and cystic fibrosis airway epithelium
19. Effect of extracellular ATP and UTP on fluid transport by human nasal epithelial cells in culture
20. Nucleotide-induced mucin release from primary hamster tracheal surface epithelial cells involves the P2U purinoceptor
21. P2U purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells
22. Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells
23. 2 receptor in primate lung tissue by nonisotopic in situ hybridization
24. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
25. Aerosolization of P2Y2-receptor agonists enhances mucociliary clearance in sheep
26. 2 receptor agonist, stimulates mucociliary clearance and enhances sputum expectoration
27. Effect of aerosolized uridine 5′triphosphate on mucociliary clearance in mild chronic bronchitis
28. Effect of aerosolized uridine-5′-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia
29. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5′-polyphosphates
30. Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways
31. 2 agonist and ion channel modulator for the treatment of cystic fibrosis: Results from initial phase 1 study
32. 2 agonist INS365 of mucociliary clearance in smokers
33. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study